Orchestra BioMed Holdings, Inc. Marketable Securities, Unrealized Gain (Loss)
Orchestra BioMed Holdings, Inc. (OBIO) reported Marketable Securities, Unrealized Gain (Loss) of -$41.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2026-08-10
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-06-30 was -$41.00K.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2026-03-31 was -$100.00K.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-12-31 was $15.00K.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for the quarter ending 2025-09-30 was $29.00K, a 76.03% decline year-over-year.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2025 was $8.00K, a 87.10% decline from fiscal 2024.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2024 was $62.00K.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2023 was -$2.00K.
- Orchestra BioMed Holdings, Inc. marketable securities, unrealized gain (loss) for fiscal 2022 was -$8.00K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.00K 10-Q · filed 2026-08-10 | -$141.00K 10-Q · filed 2026-08-10 | -$126.00K derived: sum of 3 quarters · filed 2026-08-10 | -$97.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$100.00K 10-Q · filed 2026-08-10 | -$85.00K derived: sum of 2 quarters · filed 2026-08-10 | -$56.00K derived: sum of 3 quarters · filed 2026-08-10 | -$77.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $44.00K derived: sum of 2 quarters · filed 2026-03-12 | $23.00K derived: sum of 3 quarters · filed 2026-08-10 | $8.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $29.00K 10-Q · filed 2025-11-10 | $8.00K derived: sum of 2 quarters · filed 2026-08-10 | -$7.00K 10-Q · filed 2025-11-10 | -$53.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$21.00K 10-Q · filed 2026-08-10 | -$36.00K 10-Q · filed 2026-08-10 | -$82.00K derived: sum of 3 quarters · filed 2026-08-10 | $39.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$15.00K 10-Q · filed 2026-08-10 | -$61.00K derived: sum of 2 quarters · filed 2026-08-10 | $60.00K derived: sum of 3 quarters · filed 2026-08-10 | $45.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2024-12-31 | -$46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $75.00K derived: sum of 2 quarters · filed 2026-03-12 | $60.00K derived: sum of 3 quarters · filed 2026-03-12 | $62.00K 10-K · filed 2026-03-12 |
| 2024-09-30 | $121.00K 10-Q · filed 2025-11-10 | $106.00K derived: sum of 2 quarters · filed 2025-11-10 | $108.00K 10-Q · filed 2025-11-10 | $175.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$15.00K 10-Q · filed 2025-11-10 | -$13.00K 10-Q · filed 2025-08-12 | $54.00K derived: sum of 3 quarters · filed 2025-11-10 | $73.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-03-31 | $2.00K 10-Q · filed 2025-11-10 | $69.00K derived: sum of 2 quarters · filed 2025-11-10 | $88.00K derived: sum of 3 quarters · filed 2025-11-10 | $27.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-12-31 | $67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $86.00K derived: sum of 2 quarters · filed 2025-03-31 | $25.00K derived: sum of 3 quarters · filed 2025-03-31 | -$2.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | $19.00K 10-Q · filed 2024-11-12 | -$42.00K derived: sum of 2 quarters · filed 2024-11-12 | -$69.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$61.00K 10-Q · filed 2024-11-12 | -$88.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$27.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | -$8.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| CARLSMED, INC. (CARL) | United States | $0.405B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |